September 2023 tender notification - CORRECTION (20 October 2023)
Te Pātaka Whaioranga - Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 192 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 21/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 October 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
Correction 20 October 2023
Correction to Care Pharmaceuticals’ brand name of compound electrolytes with glucose [dextrose] soln with electrolytes, 1000 ml bottle OP. The brand was incorrectly named Hydrolyte in the notification. The correct brand name is Hydralyte.
Corrections in bold and strikethrough below.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Compound electrolytes with glucose [Dextrose] |
Soln with electrolytes, 1000 ml bottle OP |
$8.55 |
$6.53 |
Hydralyte Hydrolyte – Lemonade (Care Pharmaceuticals) |
1 December 2023 |
1 May 2024 |
Pedialyte - Bubblegum (Abbott) (2504308) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows:
2. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Compound electrolytes with glucose [Dextrose] |
Soln with electrolytes, 1000 ml bottle |
$8.55 |
$6.53 |
Hydralyte Hydrolyte – Lemonade (Care Pharmaceuticals) |
5% |
1 December 2023 |
1 May 2024 |
Pedialyte – Bubblegum (Abbott) (2504308) |
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting3 |
|---|---|---|---|---|---|---|---|
|
Paclitaxel 1 |
Inj 6 mg per ml, 50 ml vial; 1 vial pack2 |
$37.89 |
Anzatax (Pfizer) |
5% |
1 March 2024 |
1 August 2024 |
Paclitaxel Ebewe (Novartis) (2207680) |
|
Paclitaxel 1 |
Inj 6 mg per ml, 16.7 ml vial; 1 vial pack2 |
$19.59 |
Anzatax (Pfizer) |
5% |
1 March 2024 |
1 August 2024 |
Paclitaxel Ebewe (Novartis) (2207664) |
|
1The price and subidy of Paclitaxel (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 March 2024. The subsidy of paclitaxel inj 1 mg for ECP (Baxter) will be reduced from $0.20 per 1 mg to $0.17 per 1 mg from 1 March 2024 in Section B of the Pharmaceutical Schedule. 2 The presentation of Pfizer’s brand of Paclitaxel inj 100 mg and inj 300 mg will be amended to Paclitaxel inj 100 mg 6 mg per ml, 16.7 ml vial and inj 300 mg 6 mg per ml, 50 ml vial in Section B of the Pharmaceutical Schedule from 1 March 2024. 3 Paclitaxel inj 6 mg per ml, 5 ml vial Paclitaxel Ebewe (Novartis) and Paclitaxel inj 6 mg per ml, 25 ml vial Paclitaxel Ebewe (Novartis) will be delisted 1 August 2024 and will not be replaced. |
|||||||
For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.